Employees: 334
Size BioNote (377740.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $337M, the 449th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩4,450 on 18 Nov 2026.
Performance Over six months the shares fell 13.6%, against -16.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 12.1% over the last twelve months (peer median +2.2%); the operating margin is 18.4% (peer median 7.9%).
Valuation It trades at 14.4× forward earnings against a peer median of 17.8× (4th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is -28%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points below its cost of capital (5.6% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩129B | ₩118B | ₩103B | ₩90.1B | ₩480B |
| Revenue growth | — | +15% | +14% | -81% | — |
| Gross profit | ₩70.0B | ₩63.0B | ₩49.3B | -₩13.4B | ₩340B |
| EBITDA | ₩33.9B | ₩26.0B | ₩20.0B | -₩39.0B | ₩302B |
| Net income | -₩209B | -₩87.5B | ₩55.3B | -₩20.5B | ₩308B |
| Free cash flow | ₩27.6B | ₩6.27B | ₩47.5B | -₩8.16B | ₩207B |
| Capital expenditure | ₩20.6B | ₩8.27B | ₩10.5B | ₩4.54B | ₩42.5B |
| Total debt | ₩4.15B | ₩3.65B | ₩3.93B | ₩4.93B | ₩1.36B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 377740.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.4% | -10.9% | 6th highest of 21 |
| 6-month return | -13.6% | -16.7% | 10th highest of 21 |
| Distance from 52-week high | -28.9% | -45.3% | 6th highest of 21 |
| Revenue growth (TTM) | +12.1% | +2.2% | 7th highest of 21 |
| Operating margin | 18.4% | 7.9% | 6th highest of 21 |
| Forward P/E | 14.4× | 17.8× | 4th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | -15.0% | 10.7% | 2nd least demanding of 15 |
| Growth delivered (Del g) | -28.5% | +0.2% | lowest of 15 |
| Hurdle (Req g minus delivered) | +13.4 pp | +4.2 pp | 7th most demanding of 15 |
| ROIC minus cost of capital | -4.0 pp | +5.4 pp | 8th lowest of 19 |
| EV / EBITDA | 3.8× | 8.9× | cheapest of 10 |
| Net debt / EBITDA | -9.4× | 1.3× | 2nd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BioNote 377740.KS | South Korea | $337M | -14% | +12% | 18% | 14.4× | -15.0% | -28.5% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 17.5× | 35.3% | +5.2% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $336M | -36% | -5% | 2% | n/a | 34.3% | +0.4% |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 25.2× | -0.3% | -0.7% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | n/a | n/a | n/a |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 3.8× | -19.9% | -0.1% |
| Tauns Laboratories 197A.T | Japan | $327M | -3% | +7% | 29% | 16.7× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $327M | -24% | -10% | 4% | n/a | 15.8% | -4.5% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $326M | -34% | -15% | -10% | 862.0× | 20.0% | -5.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $326M | -27% | +12% | -2% | n/a | n/a | n/a |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | n/a | -12.7% | -1.3% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 36.0× | 18.4% | +4.4% |
| Japan Eyewear 5889.T | Japan | $318M | -5% | +15% | 32% | 10.7× | -9.4% | +20.2% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 20.3× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 25.3× | -4.2% | -6.0% |
| Chongqing Xishan Science and Technology 688576.SS | China | $301M | -40% | -23% | -29% | 12.8× | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | n/a | n/a | n/a |